Sr. Scientist 1, In Vitro Pharmacology (Metabolic Disease)

Your Profile: We are looking for candidates with strong hands-on experience in in vitro pharmacology assay development, ideally with direct exposure to GPCR biology and/or obesity, diabetes, or broader metabolic disease research. Candidates who bring innovative thinking and a strong publication or project track record, even without extensive industry tenure, are encouraged to apply.

Education & experience: (industry experience scales inversely with degree level) Ph.D. in Pharmacology, Biology, Biochemistry, Cell Biology, or a related field, with 0–3 years of relevant industry or postdoctoral experience. Recent Ph.D. graduates with a strong record of scientific innovation and productivity are welcome to apply. M.S. in a related life sciences field, with approximately 3–6 years of relevant industry experience. B.S./B.A. in a related life sciences field, with approximately 5–8+ years of relevant industry experience. Exceptional candidates at any degree level whose expertise and track record are an outstanding match for the role's scope may be considered for Senior Scientist I. Preferred technical and scientific backgroundExperience with GPCR pharmacology and associated assay formats Experience working with biologics including antibodies, proteins, peptides, bioconjugates Background in obesity, diabetes, or broader metabolic disease biology Hands-on experience with biochemical and biophysical assay technologies Experience with cell-based functional assays and relevant cell line engineering Familiarity with automation, liquid handling, or HTS platforms is a plus Strong data analysis, interpretation, and scientific communication skills Your New TeamYou will join the Global Biology research organization and work at the interface of discovery and preclinical candidate delivery. The team collaborates closely with functional experts across Chemistry, in vivo Pharmacology, DMPK/Safety, and Formulation, contributing to a portfolio of programs through robust in vitro data generation and interpretation. Let's Bond and Be BoldWe have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold. We are committed to an inclusive recruitment process and welcome applications from all job applicants. Salary Range$110K - $150K/Yr About Zealand PharmaZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late‑stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts. Learn more at www.zealandpharma.com. Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.